DSIP (Delta Sleep-Inducing Peptide) half-life & pharmacokinetics

Reported half-life

Very short plasma half-life (minutes) due to rapid peptidase degradation. The functional effects on sleep architecture, stress adaptation, and other endpoints outlast plasma exposure through downstream neurotransmitter and hormonal cascade effects.

The half-life and pharmacokinetic profile of DSIP (Delta Sleep-Inducing Peptide) reported above is drawn from the published pre-clinical literature. Plasma half-life describes the time taken for the circulating concentration to fall by half after a single dose; tissue half-life — which may be longer for peptides retained in specific organs or matrices — is a distinct and often more relevant parameter for healing research, where the duration of exposure at the injury site matters more than the systemic exposure profile.

Routes of administration studied

• Subcutaneous injection (research; standard route)
• Intranasal (research applications requiring CNS access)
• Intraperitoneal injection (rodent research)

Different routes produce materially different pharmacokinetic profiles for the same peptide. Subcutaneous administration generally produces flatter, more sustained plasma profiles than intravenous bolus dosing; intraperitoneal administration (common in rodent models) is not directly translatable to human routes; oral administration faces the additional challenge of luminal and brush-border peptidase degradation, which is why most research peptides have very low oral bioavailability without protective formulation.

Drug class

Endogenous nonapeptide of incompletely characterised receptor pharmacology; sleep-modulating and stress-adaptation peptide with pleiotropic effects.

Mechanism context

Half-life interpretation depends on the underlying mechanism. DSIP (Delta Sleep-Inducing Peptide) acts as follows:

DSIP (Delta Sleep-Inducing Peptide, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) is a 9-amino-acid endogenous peptide first isolated by Marcel Monnier and colleagues at the University of Basel in the 1970s from cerebral venous blood of rabbits during electrical stimulation of the thalamus, which induced delta-wave EEG activity characteristic of deep slow-wave sleep. The peptide's discovery context — passive transfer of the sleep-inducing factor from stimulated to naive animals — established DSIP as a candidate endogenous sleep regulator, though subsequent research has proven the pharmacology substantially broader than the name suggests.

See the full DSIP (Delta Sleep-Inducing Peptide) research profile for the complete mechanism summary, history, study citations, and references.

Practical considerations

Short plasma half-life does not necessarily mean short duration of biological effect. Many peptides — including BPC-157, GHK-Cu, and the thymosin-derived compounds — exhibit tissue retention or mechanistic effects (gene expression, signalling cascades) that outlast plasma exposure by hours to days. The pharmacological half-life and the biological-effect half-life are distinct parameters that must both be specified in any rigorous research design. Repeated-dose protocols should account for accumulation only where tissue half-life is genuinely long; for most peptides with short plasma half-life and rapid degradation, accumulation is not a practical concern.

For dose ranges in published research, see the dosing reference page. For reconstitution guidance, see the reconstitution reference page.